Launch of in-house rater training service

Cambridge Cognition Holdings PLC

21 January 2025

 

21 January 2025

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Cambridge Cognition expands services with the launch of in-house Rater Training

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital products that advance brain health research and treatment, is pleased to announce the launch of its in-house Rater Training service.

Rater training is an important component of successful Central Nervous System (CNS) clinical studies that ensure customers' clinical trial staff collect reliable CNS study data. Adding in-house Rater Training to the Group's electronic Clinical Outcome Assessments (eCOA) and Automated Quality Assurance tools will enable the Company to become a single platform provider and expand the size of the accessible CNS clinical trials market in which its products can be utilised.

The global cognitive assessment and training healthcare market, encompassing rater training services, delivered revenues of $5.2 billion in 2023 and, notably, the services segment, which includes comprehensive rater training solutions, captured more than 50% of the total market revenue¹. This market is projected to grow at a compound annual growth rate of 27% through 2030¹.

Barbara Enger RN MSN, a CNS expert with 20 years of experience in eCOA service delivery and a consultant for Cambridge Cognition, commented:

"Rater training is a critical and mandatory component of successful CNS clinical studies. Raters must demonstrate thorough knowledge of the administration and scoring of the endpoint instrument, and must achieve acceptable levels of both intra rater and inter rater reliability prior to the start of the study and continuing through the length of the study. Equally important is the applied skill needed to administer and score the instrument electronically.  Combining those training aspects helps to ensure the collection of reliable study data."

Rob Baker, Joint Managing Director and Chief Operating Officer of Cambridge Cognition, said:

"We believe the addition of Rater Training to our portfolio will open up new markets for our world class brain health software tools, seamlessly supporting raters with advanced technology and delivering the accuracy, efficiency, and reliability that pharmaceutical companies seek in their CNS clinical trials. We are pleased to have already secured Rater Training work recently  and expect to roll out this offering to new and existing customers in the coming weeks."

1. Grand View Research (2024) 'Cognitive Assessment And Training In Healthcare Market Size, Share & Trends Analysis Report By Assessment (Biometrics, Pen & Paper-based Assessment), By Component (Solution, Services), By Application, By Region, And Segment Forecasts, 2024 - 2030', Report ID: GVR-4-68039-994-2. San Francisco: Grand View Research.

Enquiries:

Cambridge Cognition Holdings plc	Tel: [phone]
Rob Baker, Chief Operating Officer and Joint Managing Director
Panmure Liberum   Limited (NOMAD and Joint Broker)	Tel: [phone]
Freddy Crossley / Will Goode / Mark Rogers	(Corporate Broking)
Rupert Dearden	(Corporate Broking)
Dowgate Capital Limited (Joint Broker)	Tel: [phone]
David Poutney / James Serjeant
Hudson Sandler (Financial PR and IR)	Tel: [phone]
Dan de Belder / Hattie Dreyfus / Harry Griffiths	[e-mail]

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a brain health software group specializing in digital health products that advance brain health research and treatment. The company offers four core products: CANTAB® assessments-providing scientifically validated, highly sensitive, precise, and objective measures of cognitive function correlated to neural networks; a flexible and proven eCOA platform with an extensive library of instruments, enabling efficient study setup and scalable data capture; rater training services that standardise assessment delivery and scoring across clinical trials and quality assurance tools that ensure data integrity by automatically detecting deviations in administration and scoring, saving time and money. These products collectively improve clinical trial outcomes, enable early patient identification, and enhance global efficiency in healthcare and pharmaceuticals.

For further information, visit: www.cambridgecognition.com

Barbara Enger RN, MSN

Barbara Enger specializes in the area of central nervous system clinical trials, specifically in the training and quality management of study site investigators. Barbara has 20 years of CNS experience providing specialty clinical services to pharmaceutical clients which includes 4 years as a study site sub investigator in psychiatric and geriatric clinical trials. Prior to Barbara's current position in the area of CNS clinical trials, she was an advanced practice psychiatric nurse in general psychiatry, including dementia. Barbara has an MSN in Psychiatric Nursing from the University of Pennsylvania, where she held faculty appointments for 15 years.

 

END